|
|
老年患者抗凝药物使用进展
|
Abstract:
随着社会老龄化越来越明显，65岁以上老年人口越来越多，而老年患者常常合并房颤、深静脉血栓或其他心血管疾病，这些疾病都需要长期口服抗凝药。抗凝药物的使用率虽越来越高，但仍有许多患者因为害怕出血而导致抗凝不足，从而增加了致死性卒中的发生率。本文拟从老年人凝血功能、抗凝药物的种类及其特点、与其他药物之间的相互作用展开，从一些老年常见疾病的抗凝药使用情况出发，讨论老年患者抗凝药物的选择和剂量使用，并提出口服小剂量抗凝药物的安全性和可行性，为临床医师个性化地为老年患者选择合适种类和剂量的抗凝药物提供依据。
As society is becoming more and more aging, there is an increasing number of elderly people over 65 years old, and elderly patients often have atrial fibrillation, deep vein thrombosis, or other cardiovascular diseases, all of which require long-term oral anticoagulants. Although the use rate of anticoagulant drugs is increasing, there are still many patients who are afraid of bleeding and lead to insufficient anticoagulation, which increases the incidence of fatal stroke. This article intends to start from the coagulation function of the elderly, the types and characteristics of anticoagulant drugs, and the interaction with other drugs. It will review the use of anticoagulants for some common diseases in the elderly, and discuss the selection of anticoagulant drugs for elderly patients, which dosage is used, and the safety and feasibility of oral small-dose anticoagulant drugs are proposed, which provides a basis for clinicians to personally select appropriate types and dosages of anticoagulant drugs for elderly patients.
| [1] | Iyer Krishna, S. and Dayal, S. (2020) Modulators of Platelet Function in Aging. Platelets, 31, 474-482.
https://doi.org/10.1080/09537104.2019.1665641 |
| [2] | Veltkamp, R., Rizos, T. and Horstmann, S. (2013) Intracerebral Bleeding in Patients on Antithrombotic Agents. Seminars in Thrombosis and Hemostasis, 39, 963-971. https://doi.org/10.1055/s-0033-1357506 |
| [3] | Potpara, T.S., Ferro, C.J. and Lip, G.Y.H. (2018) Use of Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction. Nature Reviews Nephrology, 14, 337-351. https://doi.org/10.1038/nrneph.2018.19 |
| [4] | Eikelboom, J.W., Connolly, S.J., Gao, P., Paolasso, E., De Caterina, R., Husted, S., O’Donnell, M., Yusuf, S. and Hart, R.G. (2012) Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. Journal of Stroke and Cerebrovascular Diseases, 21, 429-435.
https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.05.007 |
| [5] | Kubitza, D., Becka, M., Wensing, G., Voith, B. and Zuehlsdorf, M. (2005) Safety, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939—An Oral, Direct Factor Xa Inhibitor-After Multiple Dosing in Healthy Male Subjects. European Journal of Clinical Pharmacology, 61, 873-880. https://doi.org/10.1007/s00228-005-0043-5 |
| [6] | St？llberger, C. and Finsterer, J. (2021) Update on Drug Interactions with Non-Vitamin-K-Antagonist Oral Anticoagulants for Stroke Prevention in Elderly Patients. Expert Review of Clinical Pharmacology, 14, 569-581.
https://doi.org/10.1080/17512433.2021.1908124 |
| [7] | da, S.R.M. (2014) Novel Oral Anticoagulants in Non-Valvular Atrial Fibrillation. Cardiovascular & Hematological Agents in Medicinal Chemistry, 12, 3-8. https://doi.org/10.2174/187152571201141201091848 |
| [8] | McBride, B.F. (2005) A Preliminary Assessment of the Critical Differences between Novel Oral Anticoagulants Currently in Development. The Journal of Clinical Pharmacology, 45, 1004-1007.
https://doi.org/10.1177/0091270005278084 |
| [9] | Lin, L.S., Zhao, L.Y., Gao, N., et al. (2020) From Multi-Target Anticoagulants to DOACs, and Intrinsic Coagulation Factor Inhibitors. Blood Reviews, 39, Article ID: 100615. https://doi.org/10.1016/j.blre.2019.100615 |
| [10] | Kuijpers, M.J., van der Meijden, P.E., Feijge, M.A., Mattheij, N.J., May, F., Govers-Riemslag, J., et al. (2014) Factor XII Regulates the Pathological Process of Thrombus Formation Onruptured Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 1674-1680. https://doi.org/10.1161/ATVBAHA.114.303315 |
| [11] | Kakkos, S.K., Kirkilesis, G.I. and Tsolakis, I.A. (2014) Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-Analysis of Phase III Trials. European Journal of Vascular and Endovascular Surgery, 48, 565-575.
https://doi.org/10.1016/j.ejvs.2014.05.001 |
| [12] | Pollack, C.V., Reilly, P.A., Eikelboom, J., et al. (2015) Idarucizumab for Dabigatran Reversal. The New England Journal of Medicine, 373, 511-520. https://doi.org/10.1056/NEJMoa1502000 |
| [13] | Patti, G., Cavallari, I., Hanon, O., et al. (2018) The Safety and Efficacy of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation in the Elderly. International Journal of Cardiology, 265, 118-124.
https://doi.org/10.1016/j.ijcard.2018.02.066 |
| [14] | Malik, A.H., Yandrapalli, S., Aronow, W.S., et al. (2019) Meta-Analysis of Direct-Acting Oral Anticoagulants Compared with Warfarin in Patients >75 Years of Age. American Journal of Cardiology, 123, 2051-2057.
https://doi.org/10.1016/j.amjcard.2019.02.060 |
| [15] | Zathar, Z., Karunatilleke, A., Fawzy, A.M., et al. (2019) Atrial Fibrillation in Older People: Concepts and Controversies. Frontiers in Medicine (Lausanne), 6, 175. https://doi.org/10.3389/fmed.2019.00175 |
| [16] | He, W., Zhang, H., Zhu, W. and Xue, Z. (2019) Effect of Anticoagulation Therapy in Older Patients with Chronic Kidney Disease and Atrial Fibrillation: A Meta-Analysis. Medicine (Baltimore), 98, e17628.
https://doi.org/10.1097/MD.0000000000017628 |
| [17] | Diener, H.C., Hart, R.G., Koudstaal, P.J., Lane, D.A. and Lip, G.Y.H. (2019) Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week. Journal of the American College of Cardiology, 73, 612-619.
https://doi.org/10.1016/j.jacc.2018.10.077 |
| [18] | Chai-Adisaksopha, C., Hillis, C., Monreal, M., Witt, D.M. and Crowther, M. (2015) Thromboembolic Events, Recurrent Bleeding and Mortality after Resuming Anticoagulant Following Gastrointestinal Bleeding. A Meta-Analysis. Thrombosis and Haemostasis, 114, 819-825. https://doi.org/10.1160/TH15-01-0063 |
| [19] | Diener, H.C., Aisenberg, J., Ansell, J., Atar, D., Breithardt, G., Eikelboom, J., Ezekowitz, M.D., Granger, C.B., Halperin, J.L., Hohnloser, S.H., Hylek, E.M., Kirchhof, P., Lane, D.A., Verheugt, F.W.A., Veltkamp, R. and Lip, G.Y.H. (2017) Choosing a Particular Oral Anticoagulant and Dose for Stroke Prevention in Individual Patients with Non-Valvular Atrial Fibrillation: Part 2. European Heart Journal, 38, 860-868.
https://doi.org/10.1093/eurheartj/ehw069 |
| [20] | Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A.J. and Kirchhof, P. (2015) Updated European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Anticoagulants Inpatients with Non-Valvular Atrial Fibrillation. Europace, 17, 1467-1507.
https://doi.org/10.1093/europace/euv309 |
| [21] | Bando, S., Nishikado, A., Hiura, N., et al. (2018) Efficacy and Safety of Rivaroxaban in Extreme Elderly Patients with Atrial Fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). Journal of Cardiology, 71, 197-201.
https://doi.org/10.1016/j.jjcc.2017.08.005 |
| [22] | Zhang, X., Cai, Q.Y., Wang, X.H., Liao, K., Hu, C.C. and Chen, H. (2021) Current Use of Rivaroxaban in Elderly Patients with Venous Thromboembolism (VTE). Journal of Thrombosis and Thrombolysis, 52, 863-871.
https://doi.org/10.1007/s11239-021-02415-5 |
| [23] | The EINSTEIN-PE Investigators (2012) Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. The New England Journal of Medicine, 366, 1287-1297. https://doi.org/10.1056/NEJMoa1113572 |
| [24] | Giustozzi, M., Franco, L., Vedovati, M.C., et al. (2019) Safety of Direct Oral Anticoagulants versus Traditional Anticoagulants in Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 48, 439-453.
https://doi.org/10.1007/s11239-019-01878-x |
| [25] | Brenner, B., Arya, R., Beyer-Westendorf, J., et al. (2019) Evaluation of Unmet Clinical Needs in Prophylaxis and Treatment of Venous Thromboembolism in At-Risk Patient Groups: Pregnancy, Elderly and Obese Patients. Thrombosis Journal, 17, 24. https://doi.org/10.1186/s12959-019-0214-8 |
| [26] | Hu, B.S., Jiang, L.X., Tang, H.X., Hu, M.Z., Yu, J. and Dai, Z.P. (2021) Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism Following Total Joint Arthroplasty or Hip Fracture Surgery: A Meta-Analysis. Journal of Orthopaedic Surgery and Research, 16, Article No. 135. https://doi.org/10.1186/s13018-021-02274-z |
| [27] | Zannad, F., Stough, W.G., Regnault, V., et al. (2013) Isthrombosis a Contributor to Heart Failure Pathophysiology? Possible Mechanisms, Therapeutic Opportunities, and Clinical Investigation Challenges. International Journal of Cardiology, 167, 1772-1782. https://doi.org/10.1016/j.ijcard.2012.12.018 |
| [28] | Eikelboom, J.W., Connolly, S.J., Bosch, J., et al. (2017) Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. The New England Journal of Medicine, 377, 1319-1330. https://doi.org/10.1056/NEJMoa1709118 |
| [29] | Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. (2013) Edoxaban versus Warfarin in Patients with Atrial Fibrillation. The New England Journal of Medicine, 369, 2093-2104. https://doi.org/10.1056/NEJMoa1310907 |
| [30] | Perera Kanjana, S., Ng Kelvin, K.H., Nayar, S., et al. (2020) Association between Low-Dose Rivaroxaban with or without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the Compass Trial. JAMA Neurology, 77, 43-48. https://doi.org/10.1001/jamaneurol.2019.2984 |
| [31] | Yiu, A. and Bajorek, B. (2019) Patient-Focused Interventions to Support Vulnerable People Using Oral Anticoagulants: A Narrative Review. Therapeutic Advances in Drug Safety, 10. https://doi.org/10.1177/2042098619847423 |
| [32] | Chan, N.C. and Eikelboom, J.W. (2019) How I Manage Anticoagulant Therapy in Older Individuals with Atrial Fibrillation or Venous Thromboembolism. Blood, 133, 2269-2278. https://doi.org/10.1182/blood-2019-01-846048 |
